Annovis Bio Inc ANVS.N, ANVS.K is expected to show no change in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Annovis Bio Inc is for a loss of 36 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 8.6% in the last three months.
Wall Street's median 12-month price target for Annovis Bio Inc is $25.00, above its last closing price of $1.44.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.29 | -0.33 | -0.43 | Missed | -30.1 |
Sep. 30 2024 | -0.54 | -0.53 | -0.97 | Missed | -84.4 |
Jun. 30 2024 | -0.69 | -0.63 | -0.32 | Beat | 49.2 |
Mar. 31 2024 | -0.84 | -0.80 | -0.10 | Beat | 87.5 |
Dec. 31 2023 | -1.39 | -1.30 | -2.24 | Missed | -71.7 |
Sep. 30 2023 | -1.06 | -1.09 | -1.63 | Missed | -49.5 |
Jun. 30 2023 | -1.11 | -1.14 | -1.07 | Beat | 6.3 |
Mar. 31 2023 | -0.33 | -0.33 | -1.19 | Missed | -256.3 |
This summary was machine generated May 6 at 22:20 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。